Showing results (391-400 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|February 4, 2012
A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancerIn Gyu Hwang, Joung-Soon Jang, Sung Yong Oh, et al.
Investigational New Drugs|September 2, 2011
Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumorsAlan H Bryce, Ravi Rao, Jann Sarkaria, et al.
Investigational New Drugs|September 2, 2011
Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignanciesAthanassios Argiris, Trevor M Feinstein, Lin Wang, et al.
Investigational New Drugs|June 5, 2012
Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D3 analogs, in-vitro and in-vivo studiesLiron Berkovich, Amnon C Sintov, Shimon Ben-Shabat
Investigational New Drugs|November 11, 2011
Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphomaJason Konner, Rachel N Grisham, Jae Park, et al.
Investigational New Drugs|August 8, 2018
Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991-2015Kota Itahashi, Toshio Shimizu, Takafumi Koyama, et al.
Investigational New Drugs|August 14, 2018
A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumorCiara M Kelly, Alexander N Shoushtari, Li-Xuan Qin, et al.
Investigational New Drugs|August 14, 2018
The Monocarboxylate transporter inhibitor Quercetin induces intracellular acidification in a mouse model of Glioblastoma Multiforme: in-vivo detection using magnetic resonance imagingMohammed Albatany, Susan Meakin, Robert Bartha
Investigational New Drugs|August 23, 2018
A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphomaTycel Phillips, Paul M Barr, Steven I Park, et al.
Investigational New Drugs|July 12, 2018
Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancerMasafumi Ikeda, Izumi Ohno, Hideki Ueno, et al.
Pageof 372